Market Research Report
Genital Herpes - Market Insights, Epidemiology and Market Forecast-2028
|Published by||DelveInsight Business Research LLP||Product code||602062|
|Published||Content info||148 Pages
Delivery time: 1-2 business days
|Genital Herpes - Market Insights, Epidemiology and Market Forecast-2028|
|Published: January 1, 2019||Content info: 148 Pages||
DelveInsight's 'Genital Herpes - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Genital Herpes in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Genital Herpes from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Study Period: 2017-2028
Genital Herpes is a sexually transmitted disease (STD) caused by the herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), where HSV is the leading cause of genital ulcers. HSV-1 is commonly found around the mouth (cold sores) and typically causes non-sexually transmitted oral herpes infection. HSV-1 commonly causes labial or pharyngeal infection, and transmission is primarily by non-genital contact. Though HSV-1 can also be transmitted to the genitals through oral sex, infections with HSV-1 can also happen from general interactions such as: eating from the same utensils; sharing lip balm or kissing.
HSV-2 typically affects the genital area and is transmitted by intimate sexual contact. HSV-2 infection is lifelong and incurable and is of particular concern due to its epidemiological synergy with HIV infection and transmission. People who are infected with HSV-2 are approximately three times more likely to become infected with HIV, and people with both HIV and genital HSV are more likely to transmit the infection to others. HSV-2 is contracted through forms of sexual contact with a person who has HSV-2. While HSV-2 infections spread through contact with a herpes sore, the AAD reports that most people contract HSV-1 from an infected person who is asymptomatic or does not have sores.
The DelveInsight Genital Herpes market report gives a thorough understanding of the Genital Herpes by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Genital Herpes in the US, Europe, and Japan.
The Genital Herpes epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by prevalent population, gender-specific prevalent population and diagnosed cases of Genital Herpes.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the prevalent population of Genital Herpes was estimated to be 83,782,625 [7MM] in 2018. United States accounts for the highest Genital Herpes cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries Germany had the highest prevalent patient population of Genital Herpes, followed by France.
This segment of the Genital Herpes report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are currently three FDA approved anti-viral therapies including Acyclovir, Famciclovir and Valacyclovir, which are being used for the treatment of Genital herpes in the United States. However these drugs have shown to be effective in managing the Genital Herpes frequent recurrence and healing of lesions but they are not fully potent in clearing the underline HSV infection. Also these drugs are associated with certain toxicity and subsequently virus are developing resistance against the existing batch of antivirals highlighting the need of innovative drugs. Curative drugs and vaccines remains one of the major unmet medical need in this space. Detailed chapters for all of these marketed drugs along with late phase promising candidates like Pritelivir and GEN-003 have been covered in the report.
The Genital Herpes market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Genital Herpes was estimated to be USD 1,211.3 million in 2018. The United States accounts for the largest market size of Genital Herpes, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
The dynamics of Genital Herpes market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Genital Herpes. Upcoming therapies such as Pritelivir (Aicuris) and GEN-003 (Genocea), have the potential to create a significant positive shift in the Genital Herpes market size. The United States accounts for the largest market size of Genital Herpes, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The market size of Genital Herpes includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.
To counter current unmet needs of the market and to provide better treatment options for Genital Herpes, several companies are working robustly on developing new therapies with novel mechanism of action.
Key Cross Competition 101